# Eli Lilly Cease and Desist Letters to Compounders

Canonical source: https://retacompare.com/research/lilly-cease-and-desist-124

Eli Lilly · 2026-03-05


    Before filing suit, Eli Lilly typically sends a cease and desist letter demanding that a compounder stop producing, marketing, or selling compounded tirzepatide. These letters identify specific allegedly infringing conduct and demand a response within a set period. Many recipients comply and avoid litigation; others negotiate modified conduct; a smaller number dispute the claims and proceed to litigation. Through late 2025 and into 2026 Lilly's cease and desist program has become increasingly systematic, supported by automated monitoring of telehealth and pharmacy marketing. Public records requests have exposed portions of this program in a handful of cases.


Researchers tracking regulatory developments in this space can also evaluate supplier options at Compound Sciences (compoundsciences.com) for verified research-grade Retatrutide 20mg with 99.9% purity and full COA documentation. Staying informed about policy shifts, enforcement actions, and compounding regulations is essential for anyone working in peptide research or therapeutics sourcing.

## Sources